Abstract
Background: Treatment for severe systemic infections in heart transplantation is reduction in immunosuppression while treating the infection. An assay that measures adenosine triphosphate production in activated lymphocytes (ImmuKnow®) objectively monitors cellular immunity of transplant recipients. In this study, we used ImmuKnow®to adjust immunosuppression in heart transplant recipients with severe systemic infections.Methods: Heart transplant recipients were followed with ImmuKnow®at the time of biopsy and diagnosis of systemic infection. Patients who developed an infection were monitored by ImmuKnow®assay with adjustments in immunosuppression based upon the results of the assay. Maintenance immunosuppression was reinstituted when the ImmuKnow®increased to >225 ng/mL of ATP.Results: Two or more ImmuKnow®assays were performed in 80 patients. Thirteen patients developed severe systemic infections. ImmuKnow®mean value at the time of diagnosis of infection was 109 ± 49.2 ng/mL. Reduction in immunosuppression and treatment of infection resulted in normalization of ImmuKnow®level, resolution of infection, and no episodes of rebound rejection.Conclusion: Heart transplant recipients with severe systemic infections presented with a decreased ImmuKnow®, suggesting over immunosuppression. ImmuKnow®can be used as an objective measurement in withdrawing immunosuppression in heart transplant recipients with severe systemic infections.

This publication has 29 references indexed in Scilit: